Omalizumab In Chronic Inducible Urticaria: A Real-Life Study Of Efficacy, Safety, Predictors Of Treatment Outcome And Time To Response
CLINICAL AND EXPERIMENTAL ALLERGY(2021)
摘要
Chronic inducible urticaria (CIndU) is characterized by wheals, angioedema or both in response to specific and definite triggers[1] . Half of CIndU patients are refractory to H1 -antihistamine treatment even at higher doses[2] . Multiple studies have proven the benefits of omalizumab in chronic spontaneous urticaria[3] . Real life data on the efficacy and safety of omalizumab treatment in CIndU are limited[4, 5] .
更多查看译文
关键词
chronic inducible urticaria,omalizumab,treatment outcome,real-life
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要